Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Avadel sells LUMRYZ, a once-at-bedtime medicine for narcolepsy, to patients and prescribers in the United States.
Avadel is a small specialty drugmaker with one main job: selling LUMRYZ, a medicine for people with narcolepsy, a sleep disorder that makes it hard to stay awake during the day. LUMRYZ is a form of oxybate, the same active ingredient used in older narcolepsy drugs, but delivered as a single dose taken at bedtime instead of two doses split across the night. That convenience is the whole pitch — patients get their full night's medicine in one go rather than waking up for a second dose.
The people who pay are patients and the prescribers who write the scripts, though in practice most of the money flows through insurers and pharmacy benefit managers who decide whether to cover the drug. Avadel's challenge is convincing doctors to switch patients off the two-dose incumbents made by Jazz Pharmaceuticals, and convincing payers that a once-nightly option is worth covering. That fight over access and reimbursement is the real battleground, not the chemistry. Avadel is no longer a publicly traded company. Its shares stopped trading after Alkermes, a drugmaker focused on neuroscience, agreed to acquire it — the deal valued Avadel at roughly $2 billion and folded its narcolepsy franchise into Alkermes' portfolio. So the LUMRYZ business now sits inside Alkermes rather than standing on its own.
For a one-product company, everything rides on that product: manufacturing, marketing, and payer contracts all point at LUMRYZ. That makes Avadel's economics simple but fragile — a single drug either wins coverage and prescriptions or it doesn't, and there's little else to fall back on. The Alkermes deal was essentially a bet that a convenient once-nightly narcolepsy medicine is worth owning outright.
Saved answer · last researched 15 Nov 2026